The mission of The DOLF Project is to develop and test improved treatments for onchocerciasis and lymphatic filariasis that will enhance efforts to control and eliminate these important neglected tropical diseases.
NEWS & EVENTS
Eleven DOLF Project publications on triple drug (IDA) mass drug administration for elimination of lymphatic filariasis have now been bundled as a PLoS Collection
PloS “Collections” are useful for readers and researchers alike, because provide easy access to related articles on high priority topics that have been published in PLoS journals at different times. This collection (published June 16, 2022) focuses on clinical trials and community studies of the safety, efficacy, and acceptability of the triple drug regimen IDA […]
DOLF Team receives a $1.8 million Bill and Melinda Gates Foundation Grant to Explore Lymphatic Filariasis Elimination in Indonesia
Over a decade ago, Indonesia had one of the largest populations endemic for lymphatic filariasis (LF) in the world with 50% of the districts endemic for this mosquito borne disease. The country consists of 6,000 inhabited island and stretches over 3,000 miles from east to west. While some districts have eliminated LF by mass drug […]
The DOLF Team’s Work to Improve Prospects for Elimination of LF Featured in a Special Supplement Published in the Am. J. Trop. Med. Hyg. (March 2022)
The DOLF project (www.dolfproject.wustl.edu) led clinical trials and community studies of the safety and efficacy of a single-dose triple-drug therapy (IDA) for Lymphatic Filariasis (LF). IDA is now being used in mass drug administration (MDA) programs in many countries to accelerate LF elimination. This work was supported by grants from the Bill & Melinda Gates […]
